Whilst I agree with your sentiments, I'm still concerned about the actual timing.
DSMB have a job to do. To analyse the data as per the trial design & criteria. The question is, what information will be shared and by whom once the first interim analysis is completed? Is there a time lag, between the release of this information and the FDA formal assessment?
IMO, if we don't get overwhelming success from the first interim analysis then MSB' SP will suffer badly. As the negativity will be emphasised without any considerations for the details e.g. that Rem-L actually works. Nor the fact that 2nd or 3rd interim analysis will come in a few weeks time.
I'm still hoping for DSMB to come back with a stop trial decision due to overwhelming efficacy, but the risks are still there.
MSB Price at posting:
$5.18 Sentiment: Buy Disclosure: Held
